Derek S Tsang1,2, Louise Murray1,3, Vijay Ramaswamy2, Michal Zapotocky2,4, Uri Tabori2, Ute Bartels2, Annie Huang2,5, Peter B Dirks6, Michael D Taylor6, Cynthia Hawkins5, Eric Bouffet2, Normand Laperriere1,2. 1. Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. 2. Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Canada. 3. Radiotherapy Research Group, University of Leeds, Leeds, United Kingdom. 4. Department of Pediatric Haematology and Oncology, 2nd Medical School, Charles University and University Hospital Motol, Prague, Czech Republic. 5. Pediatric Laboratory Medicine, Hospital for Sick Children, Toronto, Canada. 6. Division of Neurosurgery, Hospital for Sick Children, Toronto, Canada.
Abstract
BACKGROUND: The goal of this study was to evaluate outcomes in children with relapsed, molecularly characterized intracranial ependymoma treated with or without craniospinal irradiation (CSI) as part of a course of repeat radiation therapy (re-RT). METHODS: This was a retrospective cohort study of 31 children. Patients with distant relapse received CSI as part of re-RT. For patients with locally recurrent ependymoma, those treated before 2012 were re-irradiated with focal re-RT. In 2012, institutional practice changed to offer CSI, followed by boost re-RT to the site of resected or gross disease. RESULTS: Median follow-up was 5.5 years. Of 9 patients with distant relapse after initial RT, 2-year freedom from progression (FFP) and overall survival (OS) were 12.5% and 62.5%, respectively. There were 22 patients with local failure after initial RT. In these patients, use of CSI during re-RT was associated with improvement in 5-year FFP (83.3% with CSI vs 15.2% with focal re-RT only, P = 0.030). In the subgroup of patients with infratentorial primary disease, CSI during re-RT also improved 5-year FFP (100% with CSI, 10.0% with focal re-RT only, P = 0.036). Twenty-three patients had known molecular status; all had posterior fossa group A tumors (n = 17) or tumors with a RELA (v-rel avian reticuloendotheliosis viral oncogene homolog A) fusion (n = 6). No patient developed radiation necrosis after fractionated re-RT, though almost all survivors required assistance throughout formal schooling. Five out of 10 long-term survivors have not developed neuroendocrine deficits. CONCLUSIONS: Re-irradiation with CSI is a safe and effective treatment for children with locally recurrent ependymoma and improves disease control compared with focal re-irradiation, with the benefit most apparent for those with infratentorial primary tumors.
BACKGROUND: The goal of this study was to evaluate outcomes in children with relapsed, molecularly characterized intracranial ependymoma treated with or without craniospinal irradiation (CSI) as part of a course of repeat radiation therapy (re-RT). METHODS: This was a retrospective cohort study of 31 children. Patients with distant relapse received CSI as part of re-RT. For patients with locally recurrent ependymoma, those treated before 2012 were re-irradiated with focal re-RT. In 2012, institutional practice changed to offer CSI, followed by boost re-RT to the site of resected or gross disease. RESULTS: Median follow-up was 5.5 years. Of 9 patients with distant relapse after initial RT, 2-year freedom from progression (FFP) and overall survival (OS) were 12.5% and 62.5%, respectively. There were 22 patients with local failure after initial RT. In these patients, use of CSI during re-RT was associated with improvement in 5-year FFP (83.3% with CSI vs 15.2% with focal re-RT only, P = 0.030). In the subgroup of patients with infratentorial primary disease, CSI during re-RT also improved 5-year FFP (100% with CSI, 10.0% with focal re-RT only, P = 0.036). Twenty-three patients had known molecular status; all had posterior fossa group A tumors (n = 17) or tumors with a RELA (v-rel avian reticuloendotheliosis viral oncogene homolog A) fusion (n = 6). No patient developed radiation necrosis after fractionated re-RT, though almost all survivors required assistance throughout formal schooling. Five out of 10 long-term survivors have not developed neuroendocrine deficits. CONCLUSIONS: Re-irradiation with CSI is a safe and effective treatment for children with locally recurrent ependymoma and improves disease control compared with focal re-irradiation, with the benefit most apparent for those with infratentorial primary tumors.
Authors: Pooja Panwalkar; Jonathan Clark; Vijay Ramaswamy; Debra Hawes; Fusheng Yang; Christopher Dunham; Stephen Yip; Juliette Hukin; Yilun Sun; Matthew J Schipper; Lukas Chavez; Ashley Margol; Melike Pekmezci; Chan Chung; Adam Banda; Jill M Bayliss; Sarah J Curry; Mariarita Santi; Fausto J Rodriguez; Matija Snuderl; Matthias A Karajannis; Amanda M Saratsis; Craig M Horbinski; Anne-Sophie Carret; Beverly Wilson; Donna Johnston; Lucie Lafay-Cousin; Shayna Zelcer; David Eisenstat; Marianna Silva; Katrin Scheinemann; Nada Jabado; P Daniel McNeely; Marcel Kool; Stefan M Pfister; Michael D Taylor; Cynthia Hawkins; Andrey Korshunov; Alexander R Judkins; Sriram Venneti Journal: Acta Neuropathol Date: 2017-07-21 Impact factor: 17.088
Authors: Jill Bayliss; Piali Mukherjee; Chao Lu; Siddhant U Jain; Chan Chung; Daniel Martinez; Benjamin Sabari; Ashley S Margol; Pooja Panwalkar; Abhijit Parolia; Melike Pekmezci; Richard C McEachin; Marcin Cieslik; Benita Tamrazi; Benjamin A Garcia; Gaspare La Rocca; Mariarita Santi; Peter W Lewis; Cynthia Hawkins; Ari Melnick; C David Allis; Craig B Thompson; Arul M Chinnaiyan; Alexander R Judkins; Sriram Venneti Journal: Sci Transl Med Date: 2016-11-23 Impact factor: 17.956
Authors: Frank Mendrzyk; Andrey Korshunov; Axel Benner; Grischa Toedt; Stefan Pfister; Bernhard Radlwimmer; Peter Lichter Journal: Clin Cancer Res Date: 2006-04-01 Impact factor: 12.531
Authors: Raymond B Mailhot Vega; Jane Kim; Marc Bussière; Jona Hattangadi; Abby Hollander; Jeff Michalski; Nancy J Tarbell; Torunn Yock; Shannon M MacDonald Journal: Cancer Date: 2013-09-16 Impact factor: 6.860
Authors: Vijay Ramaswamy; Thomas Hielscher; Stephen C Mack; Alvaro Lassaletta; Tong Lin; Kristian W Pajtler; David T W Jones; Betty Luu; Florence M G Cavalli; Kenneth Aldape; Marc Remke; Martin Mynarek; Stefan Rutkowski; Sridharan Gururangan; Roger E McLendon; Eric S Lipp; Christopher Dunham; Juliette Hukin; David D Eisenstat; Dorcas Fulton; Frank K H van Landeghem; Mariarita Santi; Marie-Lise C van Veelen; Erwin G Van Meir; Satoru Osuka; Xing Fan; Karin M Muraszko; Daniela P C Tirapelli; Sueli M Oba-Shinjo; Suely K N Marie; Carlos G Carlotti; Ji Yeoun Lee; Amulya A Nageswara Rao; Caterina Giannini; Claudia C Faria; Sofia Nunes; Jaume Mora; Ronald L Hamilton; Peter Hauser; Nada Jabado; Kevin Petrecca; Shin Jung; Luca Massimi; Massimo Zollo; Giuseppe Cinalli; László Bognár; Almos Klekner; Tibor Hortobágyi; Sarah Leary; Ralph P Ermoian; James M Olson; Jeffrey R Leonard; Corrine Gardner; Wieslawa A Grajkowska; Lola B Chambless; Jason Cain; Charles G Eberhart; Sama Ahsan; Maura Massimino; Felice Giangaspero; Francesca R Buttarelli; Roger J Packer; Lyndsey Emery; William H Yong; Horacio Soto; Linda M Liau; Richard Everson; Andrew Grossbach; Tarek Shalaby; Michael Grotzer; Matthias A Karajannis; David Zagzag; Helen Wheeler; Katja von Hoff; Marta M Alonso; Teresa Tuñon; Ulrich Schüller; Karel Zitterbart; Jaroslav Sterba; Jennifer A Chan; Miguel Guzman; Samer K Elbabaa; Howard Colman; Girish Dhall; Paul G Fisher; Maryam Fouladi; Amar Gajjar; Stewart Goldman; Eugene Hwang; Marcel Kool; Harshad Ladha; Elizabeth Vera-Bolanos; Khalida Wani; Frank Lieberman; Tom Mikkelsen; Antonio M Omuro; Ian F Pollack; Michael Prados; H Ian Robins; Riccardo Soffietti; Jing Wu; Phillipe Metellus; Uri Tabori; Ute Bartels; Eric Bouffet; Cynthia E Hawkins; James T Rutka; Peter Dirks; Stefan M Pfister; Thomas E Merchant; Mark R Gilbert; Terri S Armstrong; Andrey Korshunov; David W Ellison; Michael D Taylor Journal: J Clin Oncol Date: 2016-06-06 Impact factor: 44.544
Authors: Kristian W Pajtler; Stephen C Mack; Vijay Ramaswamy; Christian A Smith; Hendrik Witt; Amy Smith; Jordan R Hansford; Katja von Hoff; Karen D Wright; Eugene Hwang; Didier Frappaz; Yonehiro Kanemura; Maura Massimino; Cécile Faure-Conter; Piergiorgio Modena; Uri Tabori; Katherine E Warren; Eric C Holland; Koichi Ichimura; Felice Giangaspero; David Castel; Andreas von Deimling; Marcel Kool; Peter B Dirks; Richard G Grundy; Nicholas K Foreman; Amar Gajjar; Andrey Korshunov; Jonathan Finlay; Richard J Gilbertson; David W Ellison; Kenneth D Aldape; Thomas E Merchant; Eric Bouffet; Stefan M Pfister; Michael D Taylor Journal: Acta Neuropathol Date: 2016-11-17 Impact factor: 17.088
Authors: Maria Jesus Lobón; Francisco Bautista; François Riet; Frederic Dhermain; Sandra Canale; Christelle Dufour; Thomas Blauwblomme; Michel Zerah; Kevin Beccaria; Christian Saint-Rose; Stephanie Puget; Christian Carrie; Eric Lartigau; Pierre-Yves Bondiau; Dominique Valteau-Couanet; Jacques Grill; Stephanie Bolle Journal: Springerplus Date: 2016-06-24
Authors: Jonas E Adolph; Gudrun Fleischhack; Ruth Mikasch; Julia Zeller; Monika Warmuth-Metz; Brigitte Bison; Martin Mynarek; Stefan Rutkowski; Ulrich Schüller; Katja von Hoff; Denise Obrecht; Torsten Pietsch; Stefan M Pfister; Kristian W Pajtler; Olaf Witt; Hendrik Witt; Rolf-Dieter Kortmann; Beate Timmermann; Jürgen Krauß; Michael C Frühwald; Andreas Faldum; Robert Kwiecien; Udo Bode; Stephan Tippelt Journal: Neuro Oncol Date: 2021-06-01 Impact factor: 12.300
Authors: Rebecca M Hill; Sabine L A Plasschaert; Beate Timmermann; Christelle Dufour; Kristian Aquilina; Shivaram Avula; Laura Donovan; Maarten Lequin; Torsten Pietsch; Ulrich Thomale; Stephan Tippelt; Pieter Wesseling; Stefan Rutkowski; Steven C Clifford; Stefan M Pfister; Simon Bailey; Gudrun Fleischhack Journal: Cancers (Basel) Date: 2021-12-28 Impact factor: 6.575